- Home
- ECBK vs ENLV Comparison
ECBK vs ENLV Comparison
Compare ECBK & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | ENLV |
|---|---|---|
| Founded | 1919 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.6M | 149.0M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ECBK | ENLV |
|---|---|---|
| Price | $20.14 | $0.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | 16.6K | ★ 343.5K |
| Earning Date | 05-12-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $53.16 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $0.52 |
| 52 Week High | $20.50 | $2.10 |
Technical Indicators
Market Signals| Indicator | ECBK | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 25.06 |
| Support Level | $17.64 | N/A |
| Resistance Level | N/A | $1.25 |
| Average True Range (ATR) | 0.57 | 0.05 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 72.33 | 2.57 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.